Mumbai civic body, the Brihanmumbai Municipal Corporation (BMC), on May 12 issued a global tender for procurement of COVID-19 vaccines. Interestingly, the issued tender, which aims to procure one crore doses, bars countries that share borders with India from making bids, effectively excluding China from the process. Interested companies can make bids by May 18, while the delivery must be completed within three weeks from the placing of the… read-more
Pharmaceutical giant Zydus Cadila has announced that a dose of its COVID-19 drug 'Virafin' will cost Rs 11,995. The company has claimed that Virafin will lessen the need for oxygen in COVID-19 patients. The drug was earlier approved by the Drug Controller General of India on April 23 for treatment of mild COVID-19 cases. Meanwhile, Zydus is also in the process to launch its three-dose COVID-19 vaccine Zy-CoV-D.
Courtesy: India Today
Becoming the fifth vaccine in the list, Moderna's COVID-19 vaccine has secured emergency use authorisation by the World Health Organisation. Approved in the US on December 18, 2020, the vaccine has 94.1% efficacy, as analysed by the WHO's Strategic Advisory Group of Experts. The listing is an official process to make the vaccine available for all. Four other vaccines are Pfizer BioNTech, AstraZeneca, Serum Institute of India's Covishield, and… read-more
Delhi CM Arvind Kejriwal on April 30 urged the public to not to go to the vaccination centres on May 1 as the "vaccines have not been delivered" to them yet. "Please do not line up outside vaccination centres tomorrow. It can result in a law and order situation," said the CM. Earlier, the Centre had allowed the people aged between 18-44 to get vaccinated, starting from May 1.
Vaccine maker Bharat Biotech on April 29 announced that its COVID-19 vaccine 'Covaxin' would cost only Rs 400 per dose for the states. Earlier, the company has declared to sell the vaccine at Rs 600 for the states. Bharat Biotech said that the company is "deeply concerned with the critical pandemic circumstances." However, the vaccine will still cost Rs 1,200 for private hospitals and Rs 150 for the Centre.
Courtesy: The News Minute
Bharat Biotech on April 24 announced to sell its COVID-19 vaccine Covaxin at Rs 1,200 for private hospitals and Rs 600 for state governments. The firm said that Covaxin is a "highly purified vaccine" and is expensive to manufacture. Meanwhile, the other vaccine maker, Serum Institute of India, would be selling its vaccine 'Covishield' at a price of Rs 400 for states and at Rs 600 for private hospitals.… read-more
Former PM Manmohan Singh on April 18 wrote to PM Narendra Modi requesting to bring the vaccine procurement and distribution data in public domain. He advised to accelerate the vaccine distribution across all states by eliminating domestic trials of vaccines approved by legitimate authorities abroad. Suggesting compulsory licensing provision for pharmaceutical companies to speed up vaccine manufacturing, Singh requested to allow states to… read-more
Courtesy: Indian Express
The Indian subject expert committee on April 12, has approved the Russian Vaccine Sputnik V for the emergency use. This approval was made during the time of vaccine shortage in various states of the country. Partnered with Russian manufacturers, Dr. Reddy’s Laboratories will receive 100 million doses of the Sputnik V vaccine as agreed. Earlier, the expert committee sought information on Sputnik V vaccine clinical trials.
Courtesy: Deccan Herald
Punjab CM Amarinder Singh said his state has only five days of vaccines left; three if it reached its target of two lakh shots per day, and he called on the centre to rush the next batch of vaccines. Singh has written to PM Narendra Modi and the Union Health Minister Dr Harsh Vardhan for vaccine supply schedules. The central government, however, stated that there is no shortage of vaccines.
World’s only single-shot COVID-19 vaccine, manufactured by Johnson & Johnson, will soon undergo clinical trials in India. Reportedly, J&J have sought permission from CDSCO (Central Drugs Standard Control Organisation) to start bridging clinical trials with a small number of participants. Moreover, it has partnered with Biological E to broaden its manufacturing in India. Notably, the bridging trials prove only the safety and… read-more